Investments in Variable Interest Entities (Details) - USD ($) $ in Millions |
3 Months Ended | |
|---|---|---|
Mar. 31, 2024 |
Dec. 31, 2023 |
|
| Variable Interest Entity [Line Items] | ||
| Investment in biotechnology companies that are determined to be unconsolidated variable interest entities | $ 23.8 | $ 16.4 |
| Neurimmune | ||
| Variable Interest Entity [Line Items] | ||
| Research and development costs, percentage | 100.00% | |
| Deconsolidation, gain (loss), amount | $ 3.0 |
| X | ||||||||||
- Definition Investment in biotechnology companies that are determined to be unconsolidated variable interest entities. No definition available.
|
| X | ||||||||||
- Definition Research and Development Costs, Percentage No definition available.
|
| X | ||||||||||
- Definition Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|